March 25, 2010
The Pneumococcal Awareness Council of Experts (PACE) applauds the historic signing of the Advance Market Commitment (AMC), an agreement signed Tuesday by vaccine manufacturers Pfizer and GlaxoSmithKline (GSK), to make vaccines against pneumococcal disease available at affordable prices throughout the developing world.
Through this agreement, Pfizer and GSK have agreed to supply a total of 600 million discounted doses of vaccine to developing countries over the next decade, at a price of $7 a dose for the first 20 percent and $3.50 for the remainder. These costs will be covered by the AMC fund and the Global Alliance for Vaccines and Immunization, with co-pay of $0.15 per dose from developing country governments. The agreement, five years in the making, amounts to nothing less than a sea change for vaccine delivery in the world’s poorest countries.
Since our inception, PACE and our partners have worked around the globe to raise awareness about the burden of pneumococcal disease as a leading childhood killer and to secure commitments from countries to introduce pneumococcal vaccine into their national immunization programs. We applaud the GAVI Alliance as well as the vaccine manufacturers, governments, donors and NGOs whose partnership has made this possible. We look forward to continuing our work with countries to introduce these vaccines and ultimately save millions of lives.